Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients

Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients

This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.

Study Overview

• Status: Completed
• Conditions: Myasthenia Gravis; Predictor; Thoracoscopic Thymectomy; Thymomatous; Non-Thymomatous
• Intervention / Treatment: Other: Data collection

Detailed Description

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness resulting from antibodies that target acetylcholine receptors or associated proteins at the neuromuscular junction.

Thoracoscopic thymectomy becomes more prominent than traditional transsternal thymectomy due to fewer perioperative complications with shorter hospital stays and more favorable long-term outcomes.

Prognostic outcomes following thoracoscopic thymectomy can vary significantly between non-thymomatous and thymomatous MG, necessitating a thorough investigation of these differences.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• Egypt
  • El-Gharbia
    • Tanta, El-Gharbia, Egypt, 31527
      • Tanta University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study was a combined prospective and retrospective, observational, and comparative study conducted in the neurology and cardiothoracic departments at Tanta and Zagazig University Hospitals between January 2022 and December 2025.

Description

Inclusion Criteria:

• Both sexes.
• Confirmed diagnosis of Myasthenia Gravis (MG).
• Underwent Thoracoscopic thymectomy.
• Availability of complete preoperative and postoperative records, including imaging and histopathology.
• Minimum follow-up of 9 months post-surgery.

Exclusion Criteria:

• Patients who underwent thymectomy for indications other than MG.
• Incomplete medical records or loss to follow-up before outcome assessment.
• Patients with concomitant neuromuscular disorders other than MG

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Thymomatous Myasthenia Gravis group; Thymomatous myasthenia gravis (patients with histologically confirmed thymoma).	Other: Data collection; Data were obtained from patient files, operative notes, and electronic medical records.
Non-thymomatous Myasthenia Gravis group; Non-thymomatous myasthenia gravis (patients with thymic hyperplasia or normal/ involuted thymus).	Other: Data collection; Data were obtained from patient files, operative notes, and electronic medical records.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients achieving complete stable remission	Proportion of patients achieving complete stable remission was recorded.	12 months post-procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients achieving pharmacologic remission	Proportion of patients achieving pharmacologic remission was recorded.	12 months post-procedure

Collaborators and Investigators

• Sponsor: Tanta University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): December 18, 2025
• Study Completion (Actual): December 18, 2025

Study Registration Dates

• First Submitted: December 20, 2025
• First Submitted That Met QC Criteria: December 20, 2025
• First Posted (Actual): January 6, 2026

Study Record Updates

• Last Update Posted (Actual): January 6, 2026
• Last Update Submitted That Met QC Criteria: December 20, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Site; Neoplasms; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases; Autoimmune Diseases of the Nervous System; Neurodegenerative Diseases; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Paraneoplastic Syndromes; Neuromuscular Junction Diseases; Myasthenia Gravis; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Data Collection
• Other Study ID Numbers: 36264PR13103/10/25

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
• IPD Sharing Time Frame: After the end of study for one year.
• IPD Sharing Access Criteria: The data will be available upon a reasonable request from the corresponding author.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No